Index RUT P/E 14.42 EPS (ttm) 2.58 Insider Own 2.99% Shs Outstand 31.87M Perf Week -3.68%
Market Cap 1.20B Forward P/E 5.51 EPS next Y 6.75 Insider Trans -17.33% Shs Float 31.25M Perf Month 7.33%
Income 99.89M PEG 26.21 EPS next Q 1.60 Inst Own 124.38% Short Float 19.57% Perf Quarter 18.59%
Sales 576.65M P/S 2.08 EPS this Y 14.95% Inst Trans -1.90% Short Ratio 13.09 Perf Half Y -0.03%
Book/sh 6.70 P/B 5.55 EPS next Y 7.36% ROA 8.81% Short Interest 6.11M Perf Year 56.85%
Cash/sh 8.43 P/C 4.41 EPS next 5Y 0.55% ROE 47.87% 52W Range 20.95 - 40.95 Perf YTD 20.83%
Dividend Est. - P/FCF 4.35 EPS past 5Y - ROI 16.88% 52W High -9.18% Beta 0.94
Dividend TTM - Quick Ratio 1.04 Sales past 5Y 17.87% Gross Margin 61.94% 52W Low 77.52% ATR (14) 1.26
Dividend Ex-Date - Current Ratio 1.11 EPS Y/Y TTM 1019.55% Oper. Margin 35.32% RSI (14) 54.04 Volatility 3.02% 3.25%
Employees 197 Debt/Eq 2.58 Sales Y/Y TTM 7.39% Profit Margin 17.32% Recom 1.80 Target Price 43.25
Option/Short Yes / Yes LT Debt/Eq 1.73 EPS Q/Q 52.35% Payout 0.00% Rel Volume 0.43 Prev Close 37.62
Sales Surprise 0.93% EPS Surprise 9.08% Sales Q/Q 7.18% Earnings Aug 08 AMC Avg Volume 467.04K Price 37.19
SMA20 1.72% SMA50 6.95% SMA200 9.93% Trades
Volume 198,967 Change -1.14%
Date
Action
Analyst
Rating Change
Price Target Change
Jul-30-24 Upgrade H.C. Wainwright
Neutral → Buy
$47
Jun-07-24 Upgrade Jefferies
Hold → Buy
$41 → $44
May-10-24 Downgrade Piper Sandler
Overweight → Neutral
$39
May-10-24 Downgrade Needham
Buy → Hold
Jan-04-24 Downgrade Jefferies
Buy → Hold
$30 → $37
Aug-25-23 Reiterated Needham
Buy
$35 → $36
May-02-23 Resumed Jefferies
Buy
$30
Aug-08-22 Downgrade H.C. Wainwright
Buy → Neutral
Feb-15-22 Upgrade Cantor Fitzgerald
Neutral → Overweight
$18 → $26
Aug-06-21 Downgrade Cantor Fitzgerald
Overweight → Neutral
Jan-11-21 Reiterated H.C. Wainwright
Buy
$29 → $33
Jul-14-20 Initiated BWS Financial
Sell
$8
May-27-20 Initiated Guggenheim
Neutral
Feb-19-20 Resumed Jefferies
Buy
$43
Oct-30-19 Reiterated Needham
Buy
$33 → $25
May-03-19 Resumed H.C. Wainwright
Buy
$23
Apr-12-19 Resumed Janney
Buy
$29
Mar-20-19 Initiated SunTrust
Hold
$22
Jan-16-19 Reiterated Needham
Buy
$35 → $33
Mar-08-18 Reiterated H.C. Wainwright
Buy
$21 → $33
Show Previous Ratings
Today 01:28AM
Sep-04-24 08:00AM
Aug-30-24 08:00AM
Aug-28-24 08:00AM
Aug-08-24 09:59PM
06:00PM
Loading…
06:00PM
05:25PM
04:20PM
(Associated Press Finance)
04:01PM
Aug-07-24 09:15AM
Aug-01-24 10:01AM
06:30AM
Jul-31-24 06:53AM
Jul-30-24 09:33AM
(Pharmaceutical Technology) +10.63%
Jul-29-24 06:00AM
08:00AM
Loading…
Jul-25-24 08:00AM
Jun-24-24 12:56PM
Jun-13-24 08:00AM
Jun-10-24 05:16PM
Jun-09-24 01:07AM
Jun-06-24 02:32AM
May-30-24 02:40AM
May-29-24 08:00AM
May-13-24 09:31AM
08:00AM
May-10-24 02:01PM
12:17PM
(Associated Press Finance)
09:51AM
04:48AM
May-09-24 06:00PM
05:40PM
Loading…
05:40PM
04:36PM
(Associated Press Finance)
04:02PM
04:01PM
May-07-24 09:15AM
May-02-24 10:01AM
Apr-29-24 09:45AM
08:00AM
Apr-25-24 08:00AM
Apr-11-24 08:00AM
Apr-09-24 06:00PM
Apr-03-24 08:00AM
Mar-18-24 09:40AM
Mar-13-24 12:45PM
Mar-04-24 08:28PM
Mar-01-24 12:00PM
Feb-29-24 09:40AM
Feb-28-24 11:25PM
Feb-27-24 10:41AM
(Investor's Business Daily)
Feb-23-24 10:20AM
06:09AM
(Thomson Reuters StreetEvents)
Feb-22-24 07:00PM
05:06PM
(Associated Press Finance)
04:43PM
04:09PM
04:00AM
Feb-08-24 08:00AM
Jan-31-24 08:03AM
Jan-24-24 12:10PM
Jan-18-24 07:58PM
Jan-09-24 08:34AM
Jan-04-24 10:40AM
03:17AM
Jan-03-24 08:00AM
Dec-23-23 01:01AM
Dec-21-23 05:01PM
Nov-30-23 07:04AM
Nov-27-23 08:00AM
Nov-14-23 03:08PM
Nov-09-23 08:00AM
Nov-08-23 09:53AM
09:30AM
08:00AM
Nov-07-23 04:44PM
(Associated Press Finance)
04:01PM
Nov-01-23 10:01AM
Oct-31-23 10:01AM
Oct-24-23 08:00AM
Oct-12-23 03:47AM
Oct-06-23 09:40AM
Aug-28-23 08:00AM
Aug-24-23 08:00AM
Aug-07-23 07:30AM
Aug-03-23 08:30PM
05:35PM
04:29PM
(Associated Press Finance)
04:01PM
Jul-28-23 02:56PM
Jul-20-23 08:00AM
Jul-07-23 08:52AM
Jun-22-23 08:30AM
Jun-21-23 08:00PM
Jun-01-23 08:00AM
May-18-23 01:50PM
May-09-23 03:15PM
May-04-23 06:30PM
05:55PM
04:47PM
04:01PM
May-03-23 09:15AM
Collegium Pharmaceutical, Inc. is a pharmaceutical company, which engages in development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR, Belbuca, and Symproic. The company was founded by Michael Thomas Heffernan in April 2002 and is headquartered in Stoughton, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Kuhlmann Shirley R. EVP and General Counsel Sep 05 '24 Sale 38.30 19,248 737,198 120,161 Sep 06 05:52 PM Kuhlmann Shirley R. EVP and General Counsel Sep 06 '24 Sale 37.46 977 36,594 119,184 Sep 06 05:52 PM Kuhlmann Shirley R. Officer Sep 06 '24 Proposed Sale 37.46 977 36,594 Sep 06 11:53 AM Kuhlmann Shirley R. Officer Sep 05 '24 Proposed Sale 38.30 19,248 737,197 Sep 05 04:47 PM McFarlane Neil F. Former Director Aug 12 '24 Proposed Sale 35.21 44,365 1,562,312 Aug 12 02:41 PM McFarlane Neil F. Former Director Aug 09 '24 Proposed Sale 35.20 5,000 176,007 Aug 09 04:34 PM Kuhlmann Shirley R. EVP and General Counsel Jun 03 '24 Sale 32.57 25,000 814,180 139,409 Jun 05 04:06 PM Tupper Colleen EVP & Chief Financial Officer May 28 '24 Sale 34.21 19,710 674,368 130,845 May 29 04:29 PM Dreyer Scott EVP & Chief Commercial Officer May 23 '24 Option Exercise 24.03 51,209 1,230,552 190,127 May 28 04:22 PM Dreyer Scott EVP & Chief Commercial Officer May 24 '24 Option Exercise 24.03 23,791 571,698 162,709 May 28 04:22 PM Dreyer Scott EVP & Chief Commercial Officer May 24 '24 Sale 33.98 56,807 1,930,455 105,902 May 28 04:22 PM Dreyer Scott EVP & Chief Commercial Officer May 23 '24 Sale 33.82 51,209 1,732,093 138,918 May 28 04:22 PM BOHLIN GAREN G Director May 14 '24 Option Exercise 5.73 28,985 166,084 73,760 May 16 07:20 PM BOHLIN GAREN G Director May 14 '24 Sale 32.30 28,985 936,311 44,775 May 16 07:20 PM Smith Thomas B EVP and Chief Medical Officer Feb 29 '24 Sale 36.76 995 36,580 63,409 Mar 04 04:26 PM Dreyer Scott EVP & Chief Commercial Officer Feb 26 '24 Sale 36.43 10,000 364,270 138,918 Feb 28 04:14 PM Dreyer Scott EVP & Chief Commercial Officer Jan 16 '24 Sale 32.28 23,560 760,519 111,322 Jan 18 04:19 PM Ciaffoni Joseph President and CEO Dec 21 '23 Option Exercise 21.34 4,357 92,978 279,357 Dec 22 04:36 PM Ciaffoni Joseph President and CEO Dec 21 '23 Sale 30.38 4,357 132,377 275,000 Dec 22 04:36 PM Ciaffoni Joseph President and CEO Dec 18 '23 Option Exercise 21.34 27,798 593,209 302,798 Dec 20 05:51 PM Ciaffoni Joseph President and CEO Dec 20 '23 Option Exercise 21.34 26,454 564,528 301,454 Dec 20 05:51 PM Ciaffoni Joseph President and CEO Dec 19 '23 Option Exercise 21.34 14,516 309,771 289,516 Dec 20 05:51 PM Ciaffoni Joseph President and CEO Dec 18 '23 Sale 30.04 27,798 834,935 275,000 Dec 20 05:51 PM Ciaffoni Joseph President and CEO Dec 20 '23 Sale 30.40 26,454 804,210 275,000 Dec 20 05:51 PM Ciaffoni Joseph President and CEO Dec 19 '23 Sale 30.03 14,516 435,942 275,000 Dec 20 05:51 PM Kuhlmann Shirley R. EVP and General Counsel Nov 27 '23 Option Exercise 15.90 25,600 407,040 145,118 Nov 29 04:32 PM Kuhlmann Shirley R. EVP and General Counsel Nov 27 '23 Sale 25.78 25,600 660,014 119,518 Nov 29 04:32 PM
Index - P/E - EPS (ttm) -1.19 Insider Own 8.37% Shs Outstand 114.92M Perf Week -5.27%
Market Cap 91.04M Forward P/E - EPS next Y -0.67 Insider Trans -14.52% Shs Float 114.24M Perf Month -9.99%
Income -89.91M PEG - EPS next Q -0.26 Inst Own 54.21% Short Float 15.98% Perf Quarter -24.95%
Sales 145.67M P/S 0.62 EPS this Y 40.91% Inst Trans -0.04% Short Ratio 16.84 Perf Half Y -52.27%
Book/sh -1.06 P/B - EPS next Y 9.09% ROA -35.14% Short Interest 18.26M Perf Year -37.59%
Cash/sh 1.22 P/C 0.60 EPS next 5Y - ROE - 52W Range 0.62 - 1.95 Perf YTD -15.58%
Dividend Est. - P/FCF - EPS past 5Y 16.79% ROI -149.99% 52W High -62.55% Beta 0.17
Dividend TTM - Quick Ratio 3.56 Sales past 5Y 52.21% Gross Margin 95.81% 52W Low 18.27% ATR (14) 0.06
Dividend Ex-Date - Current Ratio 3.62 EPS Y/Y TTM 45.95% Oper. Margin -89.89% RSI (14) 39.68 Volatility 9.16% 6.29%
Employees 325 Debt/Eq - Sales Y/Y TTM -0.23% Profit Margin -61.72% Recom 1.57 Target Price 4.36
Option/Short Yes / Yes LT Debt/Eq - EPS Q/Q 30.63% Payout - Rel Volume 0.46 Prev Close 0.80
Sales Surprise 18.16% EPS Surprise 32.86% Sales Q/Q 13.86% Earnings Aug 06 BMO Avg Volume 1.08M Price 0.73
SMA20 -8.46% SMA50 -15.77% SMA200 -28.52% Trades
Volume 494,583 Change -8.46%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-19-23 Initiated Piper Sandler
Overweight
$8
Nov-04-22 Upgrade RBC Capital Mkts
Sector Perform → Outperform
$7 → $10
Feb-09-22 Upgrade JP Morgan
Underweight → Neutral
$8
Nov-19-21 Resumed Morgan Stanley
Equal-Weight
$27 → $10
Aug-06-21 Downgrade SVB Leerink
Outperform → Mkt Perform
$6
Aug-06-21 Downgrade RBC Capital Mkts
Outperform → Sector Perform
$17 → $8
Aug-06-21 Downgrade JP Morgan
Overweight → Neutral
Jul-02-20 Initiated Morgan Stanley
Overweight
$34
Mar-04-20 Initiated Barclays
Overweight
$30
Jan-17-20 Downgrade Wedbush
Outperform → Neutral
Jul-23-19 Upgrade JP Morgan
Neutral → Overweight
$8 → $16
Jul-05-19 Reiterated Robert W. Baird
Outperform
$15 → $25
Jul-05-19 Reiterated H.C. Wainwright
Buy
$29 → $32
Mar-01-19 Downgrade JP Morgan
Overweight → Neutral
$21 → $7
Feb-28-19 Reiterated BofA/Merrill
Underperform
$15 → $5
Feb-27-19 Downgrade BofA/Merrill
Neutral → Underperform
$15 → $5
Jan-03-19 Upgrade BofA/Merrill
Underperform → Neutral
Dec-03-18 Initiated B. Riley FBR
Buy
$23
Nov-09-18 Upgrade Wedbush
Neutral → Outperform
$19
May-24-18 Downgrade Wedbush
Outperform → Neutral
$20 → $19
Show Previous Ratings
Sep-05-24 09:35AM
Sep-03-24 04:05PM
07:00AM
Sep-02-24 05:52AM
Aug-07-24 02:56AM
(Thomson Reuters StreetEvents)
10:30PM
Loading…
Aug-06-24 10:30PM
09:25AM
08:21AM
(Associated Press Finance)
07:30AM
Aug-01-24 04:05PM
Jul-31-24 04:05PM
Jul-24-24 11:24PM
Jul-15-24 10:56AM
Jul-05-24 09:10AM
Jul-01-24 04:05PM
04:42AM
Loading…
Jun-26-24 04:42AM
Jun-03-24 04:05PM
Jun-01-24 01:45PM
May-29-24 04:05PM
May-23-24 06:45AM
May-09-24 11:10AM
03:02AM
May-08-24 10:36PM
(Thomson Reuters StreetEvents) -7.27%
04:45PM
04:05PM
12:54PM
09:12AM
07:41AM
(Associated Press Finance)
07:30AM
07:30AM
04:30PM
Loading…
May-02-24 04:30PM
May-01-24 04:05PM
Apr-24-24 04:01PM
Apr-01-24 04:05PM
Mar-06-24 04:05PM
(PR Newswire) +6.83%
+15.04%
Mar-04-24 11:53PM
Mar-01-24 04:05PM
09:21AM
Feb-29-24 10:03PM
(Thomson Reuters StreetEvents) -12.78%
06:15PM
08:40AM
07:50AM
(Associated Press Finance)
07:30AM
Feb-25-24 01:37PM
Feb-22-24 07:00AM
Feb-14-24 10:00AM
Feb-01-24 04:05PM
(PR Newswire) +19.96%
+15.52%
Jan-08-24 08:30AM
Jan-03-24 07:00AM
Jan-02-24 04:05PM
Dec-13-23 08:47PM
Dec-10-23 08:15PM
Dec-06-23 04:00AM
Dec-01-23 04:05PM
Nov-08-23 04:05PM
(PR Newswire) -6.14%
-7.56%
Nov-06-23 07:00AM
Nov-03-23 12:46PM
Nov-02-23 03:30PM
09:33AM
09:20AM
07:47AM
(Associated Press Finance)
07:30AM
Oct-30-23 08:00AM
Oct-26-23 07:00AM
Oct-02-23 04:05PM
(PR Newswire) -8.96%
+5.33%
Sep-26-23 07:00AM
Sep-05-23 04:05PM
(PR Newswire) -6.62%
-7.87%
Sep-01-23 04:05PM
08:00AM
Aug-17-23 08:44AM
Aug-03-23 02:18PM
(American City Business Journals)
Aug-02-23 02:00PM
08:45AM
07:37AM
(Associated Press Finance)
07:30AM
Aug-01-23 04:05PM
Jul-26-23 07:00AM
Jul-25-23 03:00PM
Jul-19-23 08:00AM
Jul-17-23 04:05PM
Jul-05-23 04:05PM
12:00PM
Jun-28-23 08:00AM
Jun-08-23 07:40AM
Jun-01-23 04:05PM
07:00AM
May-23-23 04:05PM
May-09-23 02:59PM
May-05-23 06:07AM
May-04-23 04:09PM
01:00PM
08:55AM
07:51AM
07:45AM
May-03-23 08:46AM
May-01-23 04:10PM
(PR Newswire) +7.54%
-7.01%
04:05PM
10:01AM
Apr-27-23 10:03AM
Apr-18-23 01:30PM
Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm's compound, XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses, and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A, Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Mano Michael SVP, General Counsel&Secretary Sep 04 '24 Sale 0.72 3,971 2,866 273,881 Sep 05 04:28 PM Paulson Richard A. President and CEO Sep 04 '24 Sale 0.72 3,667 2,647 1,139,214 Sep 05 04:26 PM Mason Michael EVP, CFO & Treasurer Sep 04 '24 Sale 0.72 7,050 5,089 391,054 Sep 05 04:24 PM Cheng Sohanya Roshan EVP & Chief Commercial Officer Sep 04 '24 Sale 0.72 5,356 3,866 404,051 Sep 05 04:13 PM Paulson Richard A. President and CEO Aug 06 '24 Sale 0.93 3,608 3,355 1,142,881 Aug 08 04:31 PM Poulton Stuart EVP, Chief Development Officer Jul 30 '24 Sale 1.06 2,883 3,056 326,628 Jul 31 04:14 PM Paulson Richard A. President and CEO Jul 05 '24 Sale 0.85 3,616 3,077 1,146,489 Jul 09 04:15 PM PAKIANATHAN DEEPIKA Director Jun 05 '24 Sale 0.96 468,044 448,480 3,385 Jun 07 07:18 PM PAKIANATHAN DEEPIKA Director Jun 07 '24 Sale 0.95 231,548 220,133 0 Jun 07 07:18 PM PAKIANATHAN DEEPIKA Director Jun 06 '24 Sale 0.98 118,452 116,415 2,240 Jun 07 07:18 PM Mason Michael EVP, CFO & Treasurer Jun 04 '24 Sale 0.99 652 645 398,104 Jun 06 04:03 PM Paulson Richard A. President and CEO Jun 04 '24 Sale 0.99 3,592 3,556 1,150,105 Jun 06 04:02 PM PAKIANATHAN DEEPIKA Director Jun 03 '24 Sale 1.00 360,744 360,997 11,209 Jun 04 06:51 PM PAKIANATHAN DEEPIKA Director Jun 04 '24 Sale 0.95 341,040 324,704 7,911 Jun 04 06:51 PM PAKIANATHAN DEEPIKA Director May 31 '24 Sale 0.95 204,394 194,992 14,697 Jun 04 06:51 PM Paulson Richard A. President and CEO May 06 '24 Sale 1.13 3,576 4,041 1,153,697 May 07 04:56 PM Rangwala Reshma EVP & Chief Medical Officer Apr 22 '24 Sale 1.17 6,789 7,943 342,931 Apr 23 04:02 PM Paulson Richard A. President and CEO Apr 04 '24 Sale 1.29 3,563 4,596 1,157,273 Apr 05 05:20 PM Paulson Richard A. President and CEO Mar 05 '24 Sale 1.30 3,573 4,645 1,160,836 Mar 06 04:14 PM Rangwala Reshma EVP & Chief Medical Officer Feb 29 '24 Sale 1.17 15,667 18,330 355,689 Mar 04 07:41 PM Rangwala Reshma EVP & Chief Medical Officer Mar 01 '24 Sale 1.20 5,969 7,163 349,720 Mar 04 07:41 PM Poulton Stuart EVP, Chief Development Officer Feb 29 '24 Sale 1.17 16,311 19,084 335,666 Mar 04 07:40 PM Poulton Stuart EVP, Chief Development Officer Mar 01 '24 Sale 1.20 6,155 7,386 329,511 Mar 04 07:40 PM Mason Michael EVP, CFO & Treasurer Feb 29 '24 Sale 1.17 27,687 32,394 404,918 Mar 04 07:39 PM Mason Michael EVP, CFO & Treasurer Mar 01 '24 Sale 1.20 6,162 7,394 398,756 Mar 04 07:39 PM Mano Michael SVP, General Counsel&Secretary Feb 29 '24 Sale 1.17 16,973 19,858 281,428 Mar 04 07:38 PM Mano Michael SVP, General Counsel&Secretary Mar 01 '24 Sale 1.20 3,576 4,291 277,852 Mar 04 07:38 PM Cheng Sohanya Roshan EVP & Chief Commercial Officer Feb 29 '24 Sale 1.17 21,840 25,553 398,618 Mar 04 07:37 PM Cheng Sohanya Roshan EVP & Chief Commercial Officer Mar 01 '24 Sale 1.20 5,109 6,131 393,509 Mar 04 07:37 PM Paulson Richard A. President and CEO Feb 29 '24 Sale 1.17 80,470 94,150 1,183,783 Mar 04 07:36 PM Paulson Richard A. President and CEO Mar 01 '24 Sale 1.20 19,374 23,249 1,164,409 Mar 04 07:36 PM Mason Michael EVP, CFO & Treasurer Feb 27 '24 Sale 1.32 2,545 3,369 244,400 Feb 29 05:35 PM Poulton Stuart EVP, Chief Development Officer Feb 15 '24 Sale 1.33 5,847 7,783 163,772 Feb 20 04:59 PM Mason Michael EVP, CFO & Treasurer Feb 06 '24 Sale 1.59 4,205 6,671 246,945 Feb 08 04:36 PM Paulson Richard A. President and CEO Feb 06 '24 Sale 1.59 4,012 6,365 821,453 Feb 08 04:34 PM Paulson Richard A. President and CEO Jan 04 '24 Sale 0.82 4,114 3,373 783,465 Jan 08 09:00 PM Paulson Richard A. President and CEO Dec 04 '23 Sale 0.79 3,622 2,861 787,579 Dec 05 05:03 PM Paulson Richard A. President and CEO Nov 06 '23 Sale 0.92 3,606 3,319 791,201 Nov 07 05:32 PM Paulson Richard A. President and CEO Oct 04 '23 Sale 1.27 3,589 4,558 794,807 Oct 05 04:46 PM BOHLIN GAREN G Director Sep 12 '23 Buy 1.22 41,140 49,985 45,140 Sep 12 04:07 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
